7000 Cardinal Place
488 articles with Cardinal Health
Cardinal Health announced that its Board of Directors approved a quarterly dividend of $0.4957 per share out of the Company's capital surplus.
Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2022 revenues of $44.8 billion, an increase of 14% from the third quarter of last year.
Cardinal Health plans to release third-quarter financial results for its fiscal year 2022 on May 5 prior to the opening of trading on the New York Stock Exchange.
Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.
Cardinal Health launched the first surgical incise drape using industry-leading antiseptic Chlorhexidine Gluconate.
Cardinal Health announced that its Board of Directors approved a quarterly dividend of $0.4908 per share.
Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2022 revenues of $45.5 billion, an increase of 9% from the second quarter of last year.
Cardinal Health (NYSE: CAH) today provided a fiscal year 2022 financial update for the Medical segment.
Medically Home Announces a $110 Million Strategic Investment Led by Baxter International Inc., Global Medical Response and Cardinal Health to Advance Leadership in Hospital-Level Patient Care at Home
Medically Home announced a new, $110 million round of funding from strategic investors including Baxter International Inc., Global Medical Response and Cardinal Health who will each have representation on the company's Board.
Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2022 on February 3 prior to the opening of trading on the New York Stock Exchange.
Modern radiation therapy is tightly targeted to dramatically reduce toxicity and side effects and often can be administered on an outpatient basis.
Teva Pharmaceuticals reached a $15 million agreement with the state of Louisiana to settle claims against the company over its marketing of opioid products.
Cardinal Health plans to release first-quarter financial results for its fiscal year 2022 on November 9 prior to the opening of trading on the New York Stock Exchange.
Cardinal Health reported that fourth-quarter fiscal 2021 revenue increased 16% to $42.6 billion.
Total payment amounts are contingent on the number of governments that will agree to suspend their lawsuits as part of the deal.
Cardinal Health to Webcast Discussion of Fourth-Quarter and Year-End Results for Fiscal Year 2021 on August 5
Cardinal Health plans to release fourth-quarter and year-end financial results for its fiscal year 2021 on August 5 prior to the opening of trading on the New York Stock Exchange.
Cardinal Health™ Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK® Pediatric Indication
Cardinal Health (NYSE: CAH) today announced that LYMPHOSEEK ® has been approved for pediatric use by the U.S. Food and Drug Administration (FDA).
Cardinal Health and Telix Launch Gallium Awareness Campaign With Release of White-Paper: “Moving Beyond the Myth”
As interest and demand for more accurate prostate cancer imaging grows, and with the approval of the first Ga-68 PSMA based prostate imaging agent late last year1, Cardinal Health Nuclear & Precision Health Solutions and Telix Pharmaceuticals Inc. have developed an in-depth white-paper, entitled: “Moving beyond the Myth: Meeting the growing demand for Ga-68 radiopharmaceuticals.”
Cardinal Health announced that it is sending an irrevocable notice of early redemption to the holders of all of the Company's 3.200% notes due June 2022 that are outstanding as of the early redemption date and $262,442,000 in aggregate principal amount of the Company's 2.616% notes due June 2022.
Theranos founder Elizabeth Holmes is back in the courtroom for the first time in 15 months for a three-day hearing ahead of her criminal fraud trial.